EI-220

EI-220 is an investigational mRNA-based therapeutic being developed by Elixiron Immunotherapeutics for the treatment of cancer. As part of Elixiron's oncology pipeline, EI-220 utilizes messenger RNA technology to potentially express therapeutic proteins or antigens designed to stimulate the immune system against tumor cells. While the specific molecular target and mechanism of action have not been publicly disclosed, the program represents the company's strategic expansion into nucleic acid-based immunotherapies, complementing their existing portfolio of monoclonal antibodies and small molecule inhibitors. As of early 2024, the program is in the early stages of development.